NASDAQ: SPPISpectrum Pharmaceuticals Inc Stock
$0.71+0.04 (+5.97%)
Updated Mar 29, 2023
SPPI Price
$0.71
Fair Value Price
$1.01
Market Cap
$144.28M
52 Week Low
$0.32
52 Week High
$1.57
P/E
-1.15x
P/B
4.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$106.13M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.32
Operating Cash Flow
-$102M
Beta
1.52
Next Earnings
May 10, 2023
Ex-Dividend
N/A
Next Dividend
N/A
SPPI Overview
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how SPPI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SPPI ($0.71) is undervalued by 29.61% relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
SPPI ($0.71) is significantly undervalued by 29.61% relative to our estimate of its Fair Value price of $1.01 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
SPPI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPPI due diligence checks available for Premium users.
Be the first to know about important SPPI news, forecast changes, insider trades & much more!
SPPI News
Valuation
SPPI fair value
Fair Value of SPPI stock based on Discounted Cash Flow (DCF)
Price
$0.71
Fair Value
$1.01
Undervalued by
29.61%
SPPI ($0.71) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPPI ($0.71) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPPI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SPPI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.15x
Industry
18.17x
Market
21.81x
SPPI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.02x
Industry
4.92x
SPPI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SPPI's financial health
Profit margin
Revenue
$0.0
Net Income
-$21.9M
Profit Margin
0%
SPPI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$118.9M
Liabilities
$83.1M
Debt to equity
2.32
SPPI's short-term assets ($112.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPPI's short-term assets ($112.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPPI's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SPPI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.9M
Investing
-$1.8M
Financing
$50.5M
SPPI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SPPI vs Biotech Stocks
Spectrum Pharmaceuticals Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.